Biocon - 'VAI’ Brings Much-Needed Regulatory Respite, Says Motilal Oswal

Motilal Oswal Report

Biocon Ltd. has received ‘voluntary action indicated’ for its Biocon Park, Bengaluru. The approvals for these sites were stuck for more than 15 months.

A favorable compliance outcome provides visibility for product approvals, namely b-Bevacizumab and b-Ustekinumab. Further, the VAI classification for this park provides a boost to the Liraglutide opportunity as well.  While VAI is positive for Biocon, competition has intensified in some products over the past two years.

Biocon’s earnings declined significantly over the past two years (50% compounded decline over FY22-24), led by the lack of potential approvals for the U.S. market and increased financial leverage. With compliance in place for Biocon Park, we expect product approvals/launches to boost the company’s growth outlook over the next two-three years.

Accordingly, we maintain our Neutral stance on the stock, as the current valuation captures the earnings upside.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.